GAG
IBRX icon

GM Advisory Group’s ImmunityBio IBRX Stock Holding History

GM Advisory Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,057
Closed -$116K – 206
2021
Q4 		$116K Buy
19,057
+7,290
+62% +$54.8K 0.01% 195
2021
Q3 		$115K Buy
11,767
+455
+4% +$5.01K 0.01% 194
2021
Q2 		$162K Buy
11,312
+1,630
+17% +$26.9K 0.02% 197
2021
Q1 		$230K Sell
9,682
-2,475
-20% -$64.2K 0.03% 176
2020
Q4 		$162K Sell
12,157
-4,270
-26% -$41.1K 0.02% 171
2020
Q3 		$114K Buy
16,427
+1,087
+7% +$10.8K 0.02% 160
2020
Q2 		$188K Buy
15,340
+4,650
+43% +$26.3K 0.03% 165
2020
Q1 		$31K Buy
+10,690
New +$53.5K 0.01% 125

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GM Advisory Group's IBRX Position: Q1 2022 in Review

GM Advisory Group sold out of ImmunityBio (IBRX) in Q1 2022, closing a stake of 19,057 shares — an estimated $116K sold.

GM Advisory Group first reported a position in IBRX in Q1 2020 and held it in 8 quarters. The position peaked at $230K in Q1 2021. 149 funds tracked by Wall St. Rank hold IBRX as of Q1 2022.

  • GM Advisory Group reported no remaining ImmunityBio position as of Q1 2022 after selling out during the quarter.
  • GM Advisory Group sold 19,057 ImmunityBio shares in Q1 2022, an estimated $116K.
  • GM Advisory Group first reported a position in ImmunityBio in Q1 2020 and held it in 8 quarters.
  • GM Advisory Group's ImmunityBio position peaked at $230K in Q1 2021.
  • 149 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2022.

Based on GM Advisory Group's 13F filing for Q1 2022, filed 13 May 2022.